Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform
María Garranzo‐Asensio, Ana Guzmán‐Aránguez, Eloy Povedano, Víctor Ruiz‐Valdepeñas Montiel, Carmen Povés, María Jesús Fernández‐Aceñero, Ana Montero‐Calle, Guillermo Solís‐Fernández, Servando Fernández-Díez, Jordi Camps, Meritxell Arenas, Elisabeth Rodríguez-Tomàs, Jorge Joven, Maricruz Sánchez-Martínez, Núria Rodríguez, Gemma Domínguez, Paloma Yáñez‐Sedeño, José M. Pingarrón, Susana Campuzano, Rodrigo Barderas
Abstract
The humoral immune response in cancer patients can be used for early detection of the disease. Autoantibodies raised against tumor-associated antigens (TAAs) are promising clinical biomarkers for reliable cancer diagnosis, prognosis, and therapy monitoring. In this study, an electrochemical disposable multiplexed immunosensing platform able to integrate difficult-and easy-to-express colorectal cancer (CRC) TAAs is reported for the sensitive determination of eight CRC-specific autoantibodies. Methods: The electrochemical immunosensing approach involves the use of magnetic microcarriers (MBs) as solid supports modified with covalently immobilized HaloTag fusion proteins for the selective capture of specific autoantibodies. After magnetic capture of the modified MBs onto screen-printed carbon working electrodes, the amperometric responses measured using the hydroquinone (HQ)/H2O2 system were related to the levels of autoantibodies in plasma.